S100P and familial pancreatic carcinoma: As such, except for CA19-9, Maspin, pVHL, MUC1, MUC5AC, IMP3, S100P, Mesothelin found in Liu et al.’s review, the other IHC biomarkers in the current review are potential diagnostic tools for pancreatic cancer that have been validated during the period of 2013 up to now.